Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy

Journal of Gene Medicine

Volumn 4, Issue 6, 2002, Pages 644-654

  Mann, Christopher J ^a   Honeyman, Kaite ^a   McClorey, Graham ^a   Fletcher, Sue ^a   Wilton, Stephen D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antisense oligonucleotides; Duchenne muscular dystrophy; Dystrophin; Exon skipping

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; LIPOFECTIN; MESSENGER RNA PRECURSOR; NUCLEOTIDE; OLIGONUCLEOTIDE; PLASMID DNA; PRIMER DNA;

ANIMAL MODEL; ARTICLE; CELL CULTURE; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENETIC TRANSFECTION; IN VITRO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; GENETICS; MUSCULAR DYSTROPHY; SYNTHESIS; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA PRIMERS; DYSTROPHIN; EXONS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0013181060     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.295     Document Type: Article

References (48)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51 919-928.
2. Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. N Engl J Med 1988; 318: 1363-1368.
3. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 1988; 2: 90-95.
4. Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A 1995; 92: 1401-1405.
5. Budker V, Budker T, Zhang G, Subbotin V, Loomis A, Wolff JA. Hypothesis: naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process. J Gene Med 2000; 2: 76-88.
6. Skuk D, Tremblay JP. Progress in myoblast transplantation: a potential treatment of dystrophies. Microsc Res Tech 2000; 48 213-222.
7. Ferrari G, Stornaiuolo A, Mavilio F. Failure to correct murine muscular dystrophy. Nature 2001; 411: 1014-1015.
8. Grozdanovic Z, Baumgarten HG. Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex. Histol Histopathol 1999; 14: 243-256.
9. Culligan KG, Mackey AJ, Finn DM, Maguire PB, Ohlendieck K. Role of dystrophin isoforms and associated proteins in muscular dystrophy (review). Int J Mol Med 1998; 2: 639-648.
10. Rando TA, Disatnik MH, Zhou LZ. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc Natl Acad Sci U S A 2000; 97: 5363-5368.
11. Kapsa R, Quigley A, Lynch GS, et al. In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum Gene Ther 2001; 12 629-642.
12. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104: 375-381.
13. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 2001; 98: 42-47.
14. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10: 1547-1554.
15. Temsamani J, Guinot P. Antisense oligonucleotides: a new therapeutic approach. Biotechnol Appl Biochem 1997; 26: 65-71.
16. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988; 85: 5011-5015.
17. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7 1083-1090.
18. Takeshima Y, Wada H, Yagi M, et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev 2001; 23: 788-790.
19. Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9: 330-338.
20. Sierakowska H, Sambade MJ, Agrawal S, Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci U S A 1996; 93: 12 840-12 844.
21. Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 3′ splice site pairing. J Biol Chem 2001; 276: 45 476-45 483.
22. Kole R, Sazani P. Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther 2001; 3: 229-234.
23. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992; 90: 41-54.
24. Ragor T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-650.
25. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 1998; 425: 329-336.
26. Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A 1996; 93: 5731-5736.
27. Yang Y, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703-1712.
28. Acsadi G, Lochmuller H, Jani A, et al. Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther 1996; 7: 129-140.
29. Ferrer A, Wells KE, Wells DJ. Immune responses to dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Gene Ther 2000; 7: 1439-1446.
30. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244: 1578-1580.
31. Available: http://www.anri.uwa.edu.au/AO_Nomenclature.pdf.
32. Zorn AM, Krieg PA. PCR analysis of alternative splicing pathways: identification of artifacts generated by heteroduplex formation. Biotechniques 1991; 11: 180-184.
33. Available: http://rsb.info.nih.gov/nih-image/.
34. Maquat LE. When cells stop making sense: effects of nonsense codons on RNA metabolism in vertebrate cells. RNA 1995; 1: 453-465.
35. Radojevic V, Lin S, Burgunder JM. Differential expression of dystrophin, utrophin, and dystrophin-associated proteins in human muscle culture. Cell Tissue Res 2000; 300: 447-457.
36. Nudel U, Robzyk K, Yaffe D. Expression of the putative Duchenne muscular dystrophy gene in differentiated myogenic cell cultures and in the brain. Nature 1988; 331: 635-638.
37. Phelps SF, Hauser MA, Cole NM, et al. Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum Mol Genet 1995; 4: 1251-1258.
38. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994; 4: 67-69.
39. Rowland LP. Dystrophin: a triumph of reverse genetics and the end of the beginning. N Engl J Med 1988; 318: 1392-1394.
40. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 107-129.
41. Moore MJ, Query CC, Sharp PA. Splicing of precursors to mRNA by the spliceosome. In The RNA World, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1993; 303-357.
42. Vickers TA, Ecker DJ. Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region. Nucleic Acids Res 1992; 20: 3945-3953.
43. Matveeva O, Felden B, Audlin S, Gesteland RF, Atkins JF. A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures. Nucleic Acids Res 1997; 25: 5010-5016.
44. Tennyson CN, Klamut HJ, Worton RG. The human dystrophin gene requires 16 hours to be transcribed and is cotranscriptionally spliced. Nat Genet 1995; 9: 184-190.
45. Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy. Hum Mol Genet 2000; 9: 2507-2515.
46. Tennyson CN, Shi Q, Worton RG. Stability of the human dystrophin transcript in muscle. Nucleic Acids Res 1996; 24: 3059-3064.
47. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A 1991; 88: 7595-7599.
48. Crooke RM, Graham MJ, Cooke ME, Crooke ST. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 1995; 275: 462-73.